Small and large molecule bioanalysis in GLP environment
Total Trials
17
As Lead Sponsor
1
As Collaborator
16
Total Enrollment
1,178
NCT02825537
Study of the Effect of Elastic Compression (French Class III) on Water Balance Change in Healthy Subjects
Phase: N/A
Role: Collaborator
Start: Jul 31, 2016
Completion: Aug 31, 2016
NCT03298672
Safety, Tolerability, and Pharmacokinetics Study of NDX-1017
Phase: Phase 1
Start: Oct 9, 2017
Completion: Sep 5, 2019
NCT04024371
Validating Reward-related Biomarkers (RTOC)
Start: Sep 16, 2019
Completion: Feb 1, 2021
NCT04715256
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.
Role: Lead Sponsor
Start: Jan 8, 2021
Completion: Dec 31, 2021
NCT04911725
Study of the Effect of an Elastic Compression Medical Device, on Water Balance Change in Healthy Subjects
Start: Mar 23, 2021
Completion: May 24, 2021
NCT05103891
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
Start: Sep 3, 2021
Completion: Nov 29, 2021
NCT05172492
Endocare for Pelvic-perineal Pain Related to Endometriosis Used at Home
Start: Dec 7, 2021
Completion: Sep 30, 2022
NCT05323708
Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS
Start: Mar 9, 2022
Completion: Oct 6, 2023
NCT05169671
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
Start: Mar 30, 2022
Completion: Sep 9, 2022
NCT05810740
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
Start: Aug 31, 2022
Completion: Jan 18, 2023
NCT05920408
Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours
Phase: Phase 1/2
Start: Apr 11, 2023
Completion: Oct 23, 2023
NCT05753462
Phase 1/2a for Safety, PK and PD of SQY51 in Paediatric and Adult Patients Duchenne Muscular Dystrophy
Start: Apr 26, 2023
Completion: Feb 28, 2025
NCT06193200
Evaluate the Neurological Effects of EryDex on Subjects With A-T
Phase: Phase 3
Start: Jun 24, 2024
Completion: Dec 31, 2025
NCT06721091
Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males
Start: Dec 3, 2024
Completion: Nov 30, 2025
NCT06664853
Open-Label Extension of EryDex Study IEDAT-04-2022
Start: Dec 11, 2024
Completion: Nov 30, 2026
NCT06722820
Study to Evaluate LPH-5 in Healthy Subjects
Start: Apr 30, 2025
NCT06736223
Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function
Start: May 28, 2025
Completion: Aug 31, 2025
Loading map...